Skip to content
Clinical Trials – home

Octreotide: A Comprehensive Guide for Patients

5 / 9
trials open to patients / all trials
17+
Countries

In short

Octreotide, a synthetic analog of somatostatin, is being studied in clinical trials for its potential benefits in treating various medical conditions. These trials aim to evaluate the efficacy and safety of octreotide in managing symptoms, improving quality of life, and potentially slowing disease progression in conditions such as neuroendocrine tumors, gastrointestinal disorders, and certain genetic diseases. This article explores the current landscape of octreotide research and its potential applications in medical treatment.

At a glance

Conditions Studied
Neuroendocrine tumors, Carcinoid syndrome, ADPKD, Angiodysplasia-related anemia, Acromegaly, Bronchorrhea
Administration
Long-acting release (LAR) formulation, intramuscular injections every 28 days
Dosage Range
10-60 mg, depending on the condition and study protocol
Primary Outcomes
Symptom reduction, disease progression slowing, quality of life improvement
Potential Benefits
Reduced diarrhea and flushing, slowed kidney volume growth, decreased transfusion requirements, improved management of airway secretions
Safety Considerations
Generally well-tolerated, potential side effects include gastrointestinal symptoms and gallbladder issues
Ongoing Research
Evaluating efficacy in various conditions, optimizing dosage and administration protocols

What is Octreotide?

Octreotide is a medication that belongs to a class of drugs called somatostatin analogs. It is a synthetic version of a naturally occurring hormone in the body called somatostatin. Octreotide is known by various brand names, including Sandostatin, Sandostatin LAR, and Siroctid. This medication is used to treat several conditions related to hormone imbalances and certain types of tumors.

Conditions Treated with Octreotide

Octreotide is used to treat a variety of medical conditions, including:

  • Acromegaly: A condition where the body produces too much growth hormone, leading to abnormal growth of body tissues
  • Neuroendocrine tumors (NETs): Rare tumors that can occur in various parts of the body, often causing symptoms like diarrhea and flushing (known as carcinoid syndrome)
  • Gastrointestinal bleeding: Specifically from small blood vessel malformations called angiodysplasias
  • Pancreatic fistula prevention: Used after pancreatic surgery to prevent leakage of pancreatic fluids
  • Congenital hyperinsulinism: A rare genetic disorder where the pancreas produces too much insulin, leading to low blood sugar in infants

How Octreotide Works

Octreotide works by mimicking the action of somatostatin, a natural hormone in the body. Its main effects include:

  • Reducing the production of certain hormones, such as growth hormone and insulin-like growth factor 1 (IGF-1)
  • Slowing down the release of hormones from hormone-producing tumors
  • Decreasing blood flow to the intestines, which can help reduce bleeding from angiodysplasias
  • Reducing the secretion of pancreatic fluids, which can help prevent complications after pancreatic surgery

Forms and Administration

Octreotide is available in different forms:

  • Short-acting form: Given as subcutaneous (under the skin) injections, usually multiple times a day
  • Long-acting release (LAR) form: Given as an intramuscular injection (into a muscle) typically once every 4 weeks. This form is also known as Octreotide LAR or Sandostatin LAR

The dosage and frequency of administration depend on the condition being treated and the patient's response to the medication.

Effectiveness of Octreotide

Research has shown that octreotide can be effective in treating various conditions:

  • In acromegaly, it can help reduce growth hormone and IGF-1 levels, leading to improvement in symptoms
  • For patients with neuroendocrine tumors, it can help control symptoms like diarrhea and flushing, and may slow tumor growth
  • In gastrointestinal bleeding from angiodysplasias, it can reduce the need for blood transfusions
  • For congenital hyperinsulinism, it can help maintain normal blood sugar levels in infants

Potential Side Effects

Like all medications, octreotide can cause side effects. Some potential side effects include:

  • Gastrointestinal symptoms such as nausea, abdominal pain, and diarrhea
  • Gallbladder problems, including gallstones
  • Injection site reactions
  • Changes in blood sugar levels

It's important to discuss potential side effects with your healthcare provider.

Ongoing Research and Future Potential

Researchers continue to study octreotide for various conditions:

  • Its potential role in slowing the progression of polycystic kidney disease (ADPKD)
  • Its effects on the immune system in patients with neuroendocrine tumors
  • Its use in preventing complications after pancreatic surgery

These ongoing studies may lead to new uses for octreotide in the future, potentially benefiting more patients with various conditions.

Questions people often ask

Conditions where Octreotide is being studied

Each condition opens its own overview and trial list

Trials with Octreotide

Recruiting trials first

See all 9 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).